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1. Introduction
This chapter provides a summary of the current literature addressing key processes and
transcriptional  regulators  of  endothelial  cell  fate  during  embryonic  blood  vascular  and
lymphatic vascular development,  and discusses the implications of these processes/regu‐
lators  during tumour vascularization.  First,  we will  address normal embryonic develop‐
ment of the vascular systems at the molecular and cellular level. With these fundamental
processes recognized, the second part the chapter will focus on how these regulators face
dysregulation during tumorigenesis  and how they consequently  facilitate  abnormal  ves‐
sel growth.
2. Blood vessel development in the embryo
During embryogenesis, the development of the vasculature occurs prior to the onset of
blood circulation, and is initiated by de novo formation of endothelial cells (EC) from meso‐
derm derived precursor cells. In a succession of morphogenic events, intricate transcription‐
al programs orchestrate the further differentiation, proliferation and migration of blood
endothelial cells (BECs) to establish the vascular systems (fig. 1). This includes assembly of
individual ECs into linear structures and the formation of lumen to facilitate the flow of
blood; the designation of arterial, venous, capillary and later lymphatic endothelial cell iden‐
tity; and the remodelling, coalescence and maturation of the primary vascular plexus to
form large heterogeneous interlaced structures, that warrants a contiguous and fully func‐
tional blood- and lymphatic vascular system.
© 2013 Overman and François; licensee InTech. This is an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
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2.1. Embryonic blood vessel morphogenesis
2.1.1. Endothelial specification and initial blood vessel formation
De novo generation of the first EC precursors in mammals occurs in the extra-embryonic meso‐
derm. The mesoderm is a hotbed for cell specification in the embryo, and the pluripotent hae‐
mangioblast ancestor of EC precursors (angioblasts) also gives rise to haematopoietic lineages
and ostensibly even smooth muscle cells (SMC)[1-5]. In addition, ECs have been shown to
share a common precursor with mesenchymal stem/stromal cells (MSC), the so-called mesen‐
chymoangioblast[6], and it has been suggested that other precursors can propagate endothelial
cell lineages in the yolk sac. Together these observations signify the differentiation potential of
these precursor cells, and impending consequences for plasticity during later remodelling and
pathologies[7-9]. During vasculogenesis, defined as de novo generation of embryonic blood
vessels, these pluripotent mesodermal progenitor cells acquire an endothelial cell (EC) precur‐
sor- or blood cell (BC) precursor- phenotype, and subsequently co-localize and aggregate in the
mesoderm to form blood islands[10-12], with the EC precursors flattened around the edges and
the BC precursors in the centre to generate the haematopoietic lineages[11-13].
2.1.2. Blood vascular lumen formation
To initiate the formation of actual vessel-like structures, the angioblasts assemble into arteri‐
al and venous cords, and in doing so form the primitive vascular plexus. These nascent
rope-like threads have a solid core and are consequently not yet able to facilitate the flow of
blood. This functional feature requires the heart of the cord to be tunnelled out, to give way
to a central continuous lumen along the length of the nascent vessel. The transition of EC
cords into vascular tubes is a process that necessitates defined EC-polarity, and a delicate
interplay between adhesion and contractility. Polarity is essential for the distribution of
membrane junction proteins and the definition of apical/luminal (inside) and basal/ablumi‐
nal (outside) surfaces. This is harmonized by the interplay between adhesion and contractili‐
ty, through the regulating of physical force propensity that accounts for the EC-flattening
against the extracellular matrix[14-16].
Two principal cellular mechanisms have been described to explain for the formation of de
novo blood vascular lumen: cord hollowing and cell hollowing[13, 16, 17]. Both mechanisms
rely on the accumulation of vacuoles, but a fundamental difference between them is re‐
vealed in the distinct nature and location of vacuole accumulation, which is usually deter‐
mined by vessel type and size. Cord hollowing is characterized by the creation of an
extracellular luminal space within a cylindrical EC-cord. This involves the loss of apical cell
adhesion between the central- but not peripheral- ECs, and results in a lumen diameter that
is enclosed by multiple ECs[14-16, 18, 19]. Cell hollowing on the other hand involves the in‐
tracellular fusion of vacuoles within a single EC to give rise to a cytoplasmic lumen that
spans the length of the cell, and typically results in vessels that have single-EC lining[17, 20].
The aorta in the mouse embryo for example relies on extracellular lumen formation as do
most major vessels[15], while intracellular lumen formation is generally the designated
mechanism for smaller vessels.
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Figure 1. Embryonic morphogenesis of the blood vasculature. Mesodermal progenitor cells give rise the vascular endo‐
thelium through a series of steps that progressively specify ECs. In the mesoderm, angioblasts (EC-precursors) are
formed and aggregate into cords or blood island, which later arrange into the primitive vascular plexus. Angiogenic
remodelling of the primary plexus gives rise to a functional vascular network, from where the lymphatic vascular sys‐
tem eventually develops.
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2.1.3. Angiogenesis and blood vessel maturation
The institution of a continuous blood vascular lumen is a milestone for the developing vas‐
cular system and paramount for further vascular development, as it permits the flow of
blood. The nascent blood vessels that constitute this primitive vascular network will subse‐
quently expand, and then functionalize, into an extensive and more intricate systemic vascu‐
lature, in two processes respectively known as angiogenesis and vessel maturation.
Angiogenesis describes the processes of branching, expansion and remodelling of the primi‐
tive vasculature in response to pro-angiogenic signals. This is different from vasculogenesis
in that the ECs are not generated by de novo differentiation of stem cells, but rather depend
on the proliferation and migration of pre-existing vascular ECs. Vessel maturation on the
other hand describes the functionalization of nascent blood vessels, and is characterized by
mural cell ensheathment of the vessel walls. The continuous mêlée between angiogenesis
and vessel maturation – wherein vessel maturation blocks angiogenic growth, and visa ver‐
sa – ensures optimal systemic blood vascular performance.
Vascular remodelling conventionally occurs through sprouting- and intussusception angio‐
genesis, and together with vessel maturation gives rise to organ specific vascular beds. Intus‐
susception angiogenesis is a process of vessel invagination wherein vessels ultimate divide
and split – which requires appreciably high levels of polarization and localized en masse loss of
cell junctions. Sprouting angiogenesis is visibly distinct from intussusception, and unsurpris‐
ingly involves the sprouting of a subset of ECs from the vascular wall to protrude into a primed
ECM. In this discrete set of ECs, the cell-cell contacts are loosened to promote a motile pheno‐
type. The actual stromal invasion requires enzymatic degradation of the basement membrane
and ECM. There is a remarkably strict hierarchy amongst the distinct EC-types in angiogenic
sprouts, as a single tip-cell (TC) leads the way, and a host of stalk-cells (SC) follow[21]. Filopo‐
dia protrude from the TC that sense the microenvironment for attractive and repulsive signals
to guide their migration, and to eventually fuse with adjacent vessels (anastomosis), while SCs
contribute principally to the recruitment of pericytes and lumen preservation, while at the
same time maintaining the connection between the TC and parent vessel.
Once the  newly formed blood vasculature  has  extended and webbed to  an appropriate
level,  the  temporal  pro-angiogenic  signal  will  fade  and  the  nascent  vessel  will  be  dis‐
posed to maturation. Blood vessels maturation primarily requires the recruitment of peri‐
cytes  and  SMCs,  to  ensheath  and  stabilize  the  vessel  wall.  This  mural  cell  coverage
strengthens the cell-cell  contacts,  decreases vessel permeability,  and assures control over
vessel  diameter  and  therefore  blood  flow.  Also,  pericytes  supress  EC  proliferation  and
promote EC survival,  resulting in a  long EC life  and a quiescent  state,  which is  typical
for mature and functional vessels.  Pericytes also subsidize the construction of the vessel
basement membrane and deposit  various ECM components into the stroma, to generate
an angiogenesis incompetent milieu.
The whole process of vessel maturation is strikingly dynamic and intermittently reversible.
Mature ECs can, conversely to quiescence, be activated by pro-angiogenic signals, upon
which pericytes detach, cell-junctions are loosened, and the ECM is primed for angiogenic
growth. In the adult, these processes are recapitulated during pathophysiological conditions
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as a means to maintain vessel perfusion and tissue oxygenation in a dynamic milieu. Pro-
angiogenic signals can, for example, originate from inflammation and hypoxia as a transient
cue, or from a more broadly encompassing and tenacious source such as a neoplasm. The
latter type of molecular (dys-) regulation results in abnormal vessel formation, and will be
discussed later in this chapter, once the transcriptional basis for EC specification and angio‐
genesis has been established.
2.2. Transcriptional basis of blood vascular endothelial cell differentiation
The complexity and significance of the numerous morphological events contributing to
blood vessel formation, as are highlighted above, underline the necessity for scrupulous reg‐
ulation to ensure that these processes occur in a spatiotemporally controlled fashion with a
high level of precision over EC behaviour (fig. 2). Copious amounts of transcription factors
are at the foundation of these coordinating programs, to guide the dynamic gene expression
profiles at different stages of embryonic EC fate determination and vascular development
(fig. 1), which are later – at least partially – recapitulated during vessel growth in the adult.
2.2.1. Ets transcription factors regulate mesodermal specification of endothelial and haematopoietic
lineages
The E-twenty-six (ETS) family is a large group of proteins, with close to thirty members in
human and mouse, that achieves transcriptional regulation by binding clusters of ETS bind‐
ing motifs on gene enhancers and promoters[22]. In itself, this conserved core DNA se‐
quence, 5’-GGA(A/T)-3’, offers little binding specificity between Ets members, and is by no
means exclusive to endothelial-associated genes. Similarly, Ets expression extends beyond
the vascular endothelium. Even so, multiple Ets members are of crucial importance for vas‐
cular development by regulating endothelial gene transcription. The way this is accomplish‐
ed despite these seemingly ubiquitous features, is illustrated by the presence of multiple
ETS motifs in large number of enhancers and promoters that regulate specific EC gene tran‐
scription. There is also a combination of distinct Ets members being expressed in cells that
are programmed to attain or maintain an EC phenotype. It is thus proposed that the combi‐
natorial effort of these transcription factors accounts for the tight control over EC differentia‐
tion[23, 24]. Complementary to interaction within the Ets family, recent studies indicate that
Ets members also affiliate with other partner proteins to this end, and that multiple Ets
members form a transcriptional network with associated partner proteins such as Tal1 and
GATA-2 to regulate EC differentiation[25]. Another method by which specificity and func‐
tion is thought to be regulated is post-translational modification, such as phosphorylation,
sumoylation and acetylation[26], while regions flanking the ETS motif on the DNA have al‐
so been shown to affect the binding specificity of some Ets members[22].
The exact mechanisms by which the individual or combinatorial Ets expression profiles ach‐
ieve endothelial gene regulation remain largely unknown, but several Ets members have
been identified in recent years to be critical at different stages during EC specification, vas‐
culogenesis and angiogenic remodelling. For example, mouse null-embryos for the ETS
translocation variant 2 (Etv2/Er71/Etsrp71) transcription factor do not form blood island due
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to lack of EC and HPC specification, and are embryonic lethal with severe blood and vascu‐
lar defects[27, 28]. Friend leukemia integration 1 (Fli-1), another Ets member, has alterna‐
tively been shown to be essential during the establishment of the vascular plexus but not for
endothelial specification[29]. Phylogenetically and functionally close to Fli-1 is ETS related
gene (Erg)[30]. This particular Ets member acts slightly later during vascular development
and is associated predominantly with angiogenesis, by controlling a host of processes such
as EC junction dynamics and migration[31, 32].
Etv2 has in recent years arisen as the master transcriptional regulator of endothelial cell fate in
mouse and zebrafish, because its function is absolutely critical for endothelial specification,
with Etv2-null embryos failing to express vital endothelial markers and being devoid of ECs.
Expression patterns have shown that Etv2 mainly functions in the embryonic mesoderm and
blood islands at around 7.5 dpc (days post coitum) in mice, and is transiently present in larger
vessels until at least 9.5 dpc[28, 33]. Mesodermally expressed Etv2 does not only direct specifi‐
cation towards EC lineages, but is also indispensible for the development of haematopoietic
cells. In support of this, the endodermal stem cell precursors common to HPCs and ECs, halt
differentiating towards haematopoietic or EC lineages prematurely in Etv2-null mice, in vas‐
cular endothelial growth factor (VEGF) receptor-2 (VEGFR2)-positive cells [28]. The vascular
endothelial growth factor receptor-2 (VEGFR-2/Flk1), receptor to VEGF-A and considered to
be one of the most potent transducers of pro-angiogenic signalling, is thus not regulated by
Etv2 in the mouse embryo. By contras, it has previously been reported that the zebrafish ortho‐
logue of Etv2, Etsrp, is required for the expression of the zebrafish VEGFR-2 orthologue,
kdr[33], and the VEGFR-2 enhancer contains an ETS motif[34].
Other endothelial genes have been shown to be transcriptionally regulated by Etv2, confirm‐
ing its essential role in early vasculogenesis (refer to table 1). For example, the angiopoietin
(Ang) receptor tyrosine kinase with immunoglobin-like and EGF-like domains-1 (Tie2) gene
is a direct target of Etv2, and is an important vascular marker that regulates angiogene‐
sis[27]. Endothelial transcription factor GATA-2 is also a likely downstream target of
Etv2[23, 28]. Similar to Etv2, GATA-2 is involved in both haemangioblast and endothelial
development, and GATA-2 is severely downregulated in Etv2-null embryos[28]. Down‐
stream targets of GATA-2 include VEGFR-2[35] and ANG-2[36], and several other genes
that encode endothelial proteins, such as Kruppel-like factor-2 (KLF2), Ets variant- (Etv6)
and myocyte enhancer factor-2 (MEF2C), have been identified to be occupied by transcrip‐
tion factor GATA-2[37], hence might be indirectly affected by Etv2 loss of function.
The bulk of transcriptional regulation by Etv2, however, is though to be achieved through
recognition of the composite FOX:ETS motif, which is exclusive to endothelial-specific en‐
hancers, and is present in approximately 23% of all endothelial genes[24]. Members of both
the forkhead and Ets transcription factor families, in particular the forkhead box protein C2
(FoxC2) and Etv2, synergistically bind this motif to activate endothelial gene expression[24].
In vivo studies in Xenopus and zebrafish embryos have identified this motif within the en‐
hancer of 11 important endothelial genes, being Mef2c, VEGFR-2, Tal1, Tie2, VE-cadherin
(Cdh5), ECE1, VEGFR-3 (Flt-4), PDGFRβ, FoxP1, NRP1 and NOTCH4[24]. Not all of these
molecular players are individually discussed in this chapter, but it is clear that the FOX:ETS
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motif is prevalent in endothelial enhancers and appreciably regulate endothelial gene tran‐
scription. In support of this, forced activity of both Etv2 and Foxc2 induces ectopic expres‐
sion of vascular markers VEGFR-2, Tie2, Tal1, NOTCH4 and VE-cadherin, while conversely,
a mutation in the FOX:ETS motif disrupts Etv2/FoxC2 function and ablates endothelial spe‐
cific LacZ expression in mice[24].
Upstream regulation of Etv2 has been an additional focus of recent studies, to further under‐
stand the mechanisms whereby endocardial and endothelial fate is determined and to trace
back the transcriptional programs even further. In mice, the homeobox transcription factor
Nkx2-5 has been shown to directly bind the Etv2 promoter and transactivate its expression in
endothelial progenitor cells within the heart in vitro and in vivo[27]. In zebrafish, Etsrp was
identified to be downstream of Foxc1a/b (FoxC1/C2 homologues found in zebrafish) in angio‐
blast development[38]. These factors were shown to be able to bind the upstream Etsrp enhanc‐
er up1,  and the knockdown of Foxc1a/b results in loss of  up1  enhancer activity to drive
transcription[38]. This supports the collaborative role of forkhead transcription factors and
Etv2 in endothelial gene expression, and adds a dimension to the transcriptional network.
Figure 2. Transcriptional hierarchy orchestrating embryonic vascular development. Endothelial cell specification is an
intricate process that relies on extensive crosstalk between transcription factors. Downstream of their transcriptional
regulation are signalling molecules that shape the cells and define EC identity and morphogenesis.
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2.2.2. Fox transcription factors regulate arteriovenous specification and angiogenesis
It is clear that forkhead transcription factor FoxC2 has an important role during EC specifi‐
cation, through the collaboration with Etv2 at early stages of embryogenesis. Notably,
FoxO1 is also able to operate synergistically with Etv2 by binding the FOX:ETS motif[24].
However, not unlike Etv2, FoxO and FoxC transcription factors also direct FOX:ETS inde‐
pendent endothelial gene transcription, which is crucial for vascular development.
Endothelial cells are specified in FoxO1-null mice, and thus differentiate beyond the
VEGFR2+ stage of Etv2-null embryos. However, embryonic lethality occurs only slightly lat‐
er due to a severe angiogenic defect, characterized by disorganized and few vessels by E9.5,
with low expression of some crucial vascular markers[39]. Amongst those downregulated is
the arterial marker Eprin-B2, a key regulator of VEGFR3 receptor internalization and trans‐
ducer of VEGF-C/PI3K/Akt signalling, so it is hypothesized that FoxO1 regulates angiogene‐
sis by controlling VEGF responsiveness[39-41]. What further underlines the importance of
FoxO1 is the elaborate control over its the transcriptional activity, which is regulated on
many levels by posttranscriptional modifications, interaction with co-activators or co-re‐
pressors, and absolute FoxO1 protein levels, to regulate localization, DNA-binding activity,
and function[42].
FoxC1 and FoxC2 are, in addition to their role in Etv2-mediated endothelial specification, re‐
quired for endothelial cells to acquire an arterial cell phenotype[43]. Both FoxC transcription
factors directly activate the transcription of the arterial cell fate promoters Notch1 and Delta-
like 4 (Dll4), and overexpression of FoxC genes results in concomitant induction of Notch
and Dll4 expression in vitro[43]. Notch signalling has been shown to be essential for arterio‐
venous (A/V) specification, by mediating the transcription of Hairy/enhancer-of-split related
with YRPW motif protein 1 and 2 (Hey1/2). Null-mice for either Notch1 or Hey1/2 have se‐
vere vascular defects, with impaired remodelling and general loss of arterial markers such
as Ephrin-B2[44]. These arteriovenous malformations are also observed in FoxC1/2 double
homozygous knockout mice, with loss of Notch1, Notch4, Dll4, Hey2 and ephrinB2, while
transcription of the venous marker chicken ovalbumin upstream promoter transcription fac‐
tor 2 (COUP-TFII/NR2F2) and the pan-endothelial marker VEGFR2 is not affected[43].
FoxC1 has recently been shown to control ECM composition and basement membrane integ‐
rity, by regulating the expression of several matrix metalloproteinases (MMPs)[45], and ge‐
netically interacting with laminin α-1(lama1)[46], respectively. The homeostasis of these
factors directly influences the vasculature’s microenvironment, and is of great relevance to
angiogenesis. In the mouse corneal stroma, MMP1a, MMP3, MMP9, MMP12 and MMP12
are upregulated in absence of FoxC1, which is associated with induced angiogenesis by the
excessive degradation of the ECM and increased bioavailability of VEGF[45]. The crosstalk
between VEGF signalling and forkhead transcription factors is thus a recurring observation,
although it is unclear if and how they physically interact. Expression levels of collagens
Col1a1, Col3a1, Col4a1 seem unaffected by loss of FoxC1[45], suggesting that FoxC1 does
not directly contribute so structural basement membrane or stromal components. However,
as mentioned, FoxC1 does interact with lama1 to support basement membrane integrity and
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vascular stability during vascular development in zebrafish, with FoxC1 morphants having
severe basement membrane defects similar to that reported for lama1[46].
The divergent roles of FoxC1/2 are not limited to orchestration blood vascular development,
and concomitantly also control the development of the lymphatic vascular system. Natural‐
ly occurring mutations in the human FoxC2 gene are associated with hereditary lymphede‐
ma-distichiasis (LD) syndrome, an autosomal dominant disorder which is characterized by
accumulation of interstitial flood leading to swelling (lymphedema), and aberrant eyelash
growth (distichiasis)[47]. Clinical studies have revealed that patient with LD have impaired
lymphatic valve function[48], and in vivo mouse studies have shown that lymphatic valves
do not form properly in FoxC2-nul mutants[49]. Also, the smooth muscle coverage of lym‐
phatic collector vessels is increased in FoxC2 heterozygous mice, which is inherent to LD,
owing to an increased expression of platelet derived growth factor β (Pdgfβ) in vivo[49].
Hence, it has been suggested that FoxC2 regulates lymphatic vessel maturation, and possi‐
bly lymphatic sprouting, by interacting with growth factors and transcription factors that
regulate lymphatic development. Notably, the lymphatic endothelial cell (LEC) receptor
VEGFR3 is thought to be upstream of FoxC2, linking pro-lymphangiogenic VEGF signalling
to FoxC2 activity[49], which supports the observation that FoxC2 mutants have increased
vSMC-mediated LEC maturation. FoxC2 has since been shown to cooperate with the master
regulator of LEC commitment prospero homeobox protein 1 (Prox1) during lymphatic valve
formation in controlling the activity of gap junction protein connexin37 (Cx37) and nuclear
factor of activated T-cells cytoplastmic-1 (NFATc1)[50]. In this context, NFATc1 activity is
controlled by VEGF-C that leads to FoxC2 interaction[51]. Compound FoxC1 heterozygous;
FoxC2 homozygous mice further have lymphatic sprouting defects during the earliest stages
of lymphangiogenesis[43].
Taken together, this suggests that FoxC signalling has critical roles during lymphangiogene‐
sis and lymphatic maturation in addition to A/V specification and angiogenesis, through co‐
operation with lymphatic specific transcription factors.
2.2.3. Members SOXF transcription factors determine A/V specification and lymphangiogenenic
switch
The three members of the SOXF group – SOX7, SOX17 and SOX18 – are all endogenously
expressed in ECs during vascular development[52], and several key functions of these tran‐
scription factors have been described over the years. This includes regulation of A/V specifi‐
cation, angiogenesis, lymphangiogenesis and red blood cell specification, but also other
roles perceivably not associated with the blood or lymphatic vasculature, such as hair folli‐
cle development and endoderm differentiation.
SOXF transcription factors belong to the SRY-box (SOX) family that is comprised of 20 mem‐
bers. SOX members are all characterized and identified by their highly homologous 79 ami‐
no acid high-mobility group (HMG) domain, which was first discovered in their founding
member sex-determining region Y (SRY)[53]. This typical SOX element binds the heptameric
consensus sequence 5’-(A/T)(A/T)CAA(A/T)G-3’[54], to induce DNA bending and regulate
the expression of a broad collection of genes during embryonic development[55]. Specificity
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and functional differentiation between SOX-groups and individual members is accomplish‐
ed by additional operative elements on the SOX transcription factors, and through associa‐
tion with partner proteins[54, 56, 57]. Their coexpression and HMG domain homology,
however, does suggest that functional redundancies or cooperative roles apply for members
within the same SOX group. However, of the SOXF group only SOX18 is endogenously ex‐
pressed during lymphatic vascular development in LEC precursors[58].
SOX18 function in vascular development has received considerable attention since the natu‐
rally occurring ragged mouse mutation, the mural counterpart of the human syndrome hy‐
potrichosis-lymphedema-telangiecstasia (HLT) and underlying cause of severe
cardiovascular and hair follicle defects, was identified in the Sox18 gene (Sox18Ra)[59]. This
mutation produces a truncated form of SOX18 that acts in a dominant negative fashion and
fails to recruit essential co-factors, and is therefor unable to induce target gene transcrip‐
tion[56, 59]. The defects in the ragged mice are much more severe than the observed pheno‐
type of Sox18-null mice[59], as truncated SOX18 competes with redundant SOXF members
to occupy the same site on the DNA. This supports the notion that redundancies exist
amongst SOXF transcription factors, and in fact it has been shown that SOX7 and SOX17 can
activate SOX18 targets by binding to SOX18 promoter elements[58].
In the zebrafish embryo, individual knockdown of either SOX7 or SOX18 causes no obvious
vascular defects, while the SOX7/18 double knockdown is characterized by partial loss of
circulation, ectopic shunts between the main artery and vein, cardiac oedema, blood pool‐
ing, and a general loss of A/V specification[60, 61]. Indeed, SOX7 and SOX18 were found to
be coexpressed in ECs and their precursors, and their combined loss of function resulted in
reduction of arterial markers Ephrin-B2, notch3 and Dll4 and ectopic expression of the ve‐
nous endothelial marker VEGFR3 in the dorsal aorta (DA)[60, 61].
Several direct SOX18 vascular target genes have been described, notably the genes encoding
the tight junction component claudin-5[62] and the vascular adhesion molecule
VCAM-1[63], which are both essential for vascular integrity and endothelial activation dur‐
ing angiogenesis. SOX18 also directly activates the expression of MMP7, EphrinB2, interleu‐
kin receptor 7 (IL-7R)[64] and Robo4[65] in vitro. Robo4 expression in vivo is correspondingly
under control of Sox7/18 activity in the mouse caudal vein, and in the intersegmental vessels
(ISV) of zebrafish embryos[65]. Archetypically, Robo4 functions in axon guidance, but has
more recently been identified as an important coordinator of EC migration during spouting
angiogenesis in zebrafish[66]. In vitro assays have further shown that compound SOX17 het‐
erozygous; SOX18-null primary ECs have a sprouting and vascular remodelling defect[67].
SOX18-null mice, although devoid of any obvious blood vascular defects, are characterized
by the lack of lymphatic vasculature. This is inherent to the Ragged mouse, and describes a
nonredundant role for SOX18 in mouse lymphatic endothelial differentiation[68]. At the on‐
set of lymphangiogenesis, SOX18 is coexpressed with COUP-TFII and drives the expression
of Prox1 in a subset of endothelial cells lining the wall of the CV. These LECs form the basis
of the lymphatic vasculature, and absolutely require transient SOX18 and COUP-TFII activi‐
ty to induce Prox1 transcription[68, 69].. SOX18-null and COUP-TFII-null mice do not ex‐
press Prox1 in the embryonic CV, are devoid of LECs, and consequently have a total lack of
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lymph sacs and lymphatic vasculature[68, 69]. However, after the initial LEC specification,
Prox1 expression becomes independent of SOX18, and later COUP-TFII, but itself remains
critical for lymphatic remodelling and maintenance of LEC identity[68, 69].
3. Blood vessel development in solid tumours
Tumour cells are characterized by chronic proliferation and immortality, due to mutations
in genes that regulate cell cycle, homeostasis and cell death[70]. As a solid tumour grows, it
is evident that the need for oxygen and nutrients increases correspondingly, and waste ma‐
terials need to be carried off in escalating amounts, which rationalizes the commonly ob‐
served tumour-induced neo-vascularisation. To accomplish this remarkable feat, tumour
cells exploit many of the vascular signalling pathways that are activated during embryogen‐
esis, but without tight spatiotemporal control (fig. 3). Vascular architecture and integrity is
therefore often compromised, promoting malign features of progressive tumours, such as
metastatic behaviour.
3.1. Characteristics of the tumour vasculature
Due to the high oxygen demand and great metabolic activity of tumour cells, the peritumor‐
al region usually becomes hypervascularised. However, this does not truly solve the prob‐
lem for tumour cells, as in their gluttony they induce constitutive pro-angiogenic signalling
that fails to generate a functional vascular network (fig. 3ab). The balance between pro-an‐
giogenic signalling and the subsequent maturation of the newly formed nascent vessels is
key for proper circulation and perfusion. Typically, vessel maturation is inadequate in tu‐
mour tissue, owing to persistent presence of pro-angiogenic factors. The overabundance of
pro-angiogenic signalling originates in part from the tumour directly, but is also a result of
the chronic hypoxic and acidic state of the tumour microenvironment. In addition, tumours
often trigger and maintain a chronic inflammatory response, wherein cells of the innate and
adaptive immune system – mostly macrophages, neutrophils, mast cells and lymphocytes –
infiltrate the tumour stoma and crosstalk with ECs to activate quiescent ECs and sustain
pro-angiogenic signalling. Although an immune response can in fact reject certain tumours,
malignant tumours and their microenvironment can generally evade immune cell mediated
destruction, and instead recruit them to their angiogenic campaign[70, 71].
However, tumour angiogenesis proceeds in an unorganized tempest of random sprouting
because the guiding signals in the stroma are disorganized, and sprouting cells are unable to
filter out any consistent cues. Abnormal shunts, including arteriovenous anastomoses, are
commonly observed due to abrogated intervascular communication leading to bi-directional
blood flow and impaired perfusion[72]. Tumours are highly diverse due to their tissue of
origin and the heterogeneity of the mutations underlying their tumorigenic state. The type
and degree of tumour vessel abnormality is correspondingly context dependent, but there
are some general traits that tumour vessels share. These regard to overall vascular organiza‐
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tion and hierarchy as a network, immediate manifestation of maturation deficiencies, and
morphology of vascular ECs.
While the dysregulation of angiogenesis causes overall hypervascularization, vessels are
distributed unevenly throughout the peritumoral region, with very low vascular density in
some areas. Moreover, large tumours instigate high tissue pressure that can compress and
constrict vessels, and vessel diameter thus becomes independent of blood flow rate[73]. Nor‐
mally, high interstitial pressure is an important queue for lymphatic vessel to drain off the
excess fluid, but this function is perturbed in tumour tissue and extravasated fluid is not the
sole cause of pressure rise[74, 75]. Where larger blood vessels in normal tissue branch into
gradually decreasing size vessels and eventually thin-walled capillaries, this obvious hierar‐
chy is often lost in tumour vasculature, and heterogeneous vessel subtypes are randomly
distributed throughout the tumour vascular bed[76, 77]. This affects, but not truly reflects,
their functional status.
Where normal vascular endothelial cells line up in the vessel wall to create a continuous bar‐
rier to maintain tissue fluid homeostasis and allow the selective diffusion and transport of
certain molecules, the tumour vasculature is characterized by loss of EC polarity and cell-
cell adhesion that results in an incontinuous and leaky vessel wall. This is aggravated by the
loosening of EC-associated mural cells, who fail attach tightly to ECs in the presence of con‐
stitutive pro-angiogenic signalling, which in turn leads to reduced vessel stability and inco‐
herent deposition of basement membrane- and ECM components[78, 79]. These resultant
vessels cannot maintain a trans-vascular pressure gradient, because excessive amounts of
fluid leak into the interstitial space through the porous vessels. Furthermore, tumour cells
can gain entrance to the vascular system, for either transport throughout the circulation, or
incorporation into the vessel wall.
The entry of tumour cells into the vasculature is a primary facilitator of distant metastasis
formation, and is importantly applicable for both blood vessel and lymphatic vessels (fig
3b). It is of note that the lymphatic system is specifically designed to not only transport im‐
mune cells, but also to absorb, and drain off, fluid and larger molecules. Therefore, lymphat‐
ic capillaries are inadvertently effective in the uptake of tumour cells, and regional lymph
node metastasis is a common indication of malignant tumour progression that is used a
prognostic tool in human cancer patients[80, 81].
Overall, tumour cells seem to be able to initiate a chronic state of angiogenesis and lym‐
phangiogenesis, but in doing so fail to create normal functional vascular networks. The sig‐
nalling programmes that underlie these tumour-induced malformations may often have
their foundation at a transcription level, with balance in transcriptional networks tipped to‐
wards proliferation of both tumour- and vascular EC proliferation and migration.
3.2. Cellular origin of the tumour derived endothelium
The vascular expansion that rapid growing tumours induce requires great numbers of vas‐
cular EC to form these structures. Tumours engage in three distinct strategies to wheel in
these recruits and promote angiogenesis. The most obvious pro-angiogenic signalling path‐
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way is that which leads to proliferation of a pre-existing vasculature, as it occurs in embry‐
onic remodelling and normal vascularization in the adult. However, tumours also promote
the mobilization and specification of bone marrow derived cells (BMDCs). In addition, tu‐
mour cells themselves can transdifferentiate into ECs to be incorporated into the tumour
vasculature (fig. 3)[82].
Figure 3. Tumour vascularization strategies originating from TF-dysregulation. (A) As it grows, a tumour adapts sever‐
al techniques to induce vascularization, either though proliferation of preexcisting peritumoral vessels or by promot‐
ing differentiation of non-EC into vascular endothelium. (B) The peritumoral and intratumoral regions get
hypervascularized by the pro-angiogenic and pro-vasculogenic signals that the tumour instigates, which facilitates
vessel intravasation metastatis through the vasculature. (C) Transciptional dysregulation underlies the angiogenic and
vasculogenic signalling that tumour emanate.
Proliferation of the existing vasculature proceeds for a large part through VEGF signalling.
The VEGF signalling axis controls angiogenic- and lymphangiogenic sprouting through reg‐
ulation of cell proliferation and migration, with a set of several VEGF ligands and VEGFR
receptors. VEGF-A is particularly angiogenic, while VEGF-C and VEGF-D are primarily
lymphangiogenic. The downstream effect however is much dependant on the VEGFR they
bind, with several possible combinations and dynamic receptor homodimerization, hetero‐
dymerization or co-receptor (NRPs) interaction adding to the complexity. In general, VEGF-
A binds to VEGFR1 or VEGFR2 with the former interaction being anti-angiogenic to due
high affinity but low downstream tyrosine kinase activity, and the latter being pro-angio‐
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genic. VEGF-C and VEGF-D on the other hand primarily bind the lymphangiogenic
VEGFR3 receptor or VEGFR2-3 heterodimers to promote lymphangiogenesis. Hence,
VEGFs, their receptors, and regulatory proteins upstream of VEGF – or signalling molecules
that crosstalk with VEGF – are beguiling (lymph-)angiogenic players[83, 84].
Recently, light has been shed on tumour signalling to neighbouring endothelium, which
convolutes this classical growth factor signalling. Microvesicles released from tumour cells
can transport genetic material and signalling molecules directly into endothelial (progenitor)
cells that can make epigenetic modification to regulatory genes and otherwise alter expres‐
sion patterns[85-88]. These microvesicles can also originate from non-tumour cells, such as
EPC, to activate angiogenic programmes in vascular ECs[89, 90]. This demonstrates that
cells residing in the tumour stroma are altered at a more fundamental level to contribute to
tumour vascularization.
Although angiogenesis is the prevailing concept that accounts for tumour vascularization, it
is becoming ever more prevalent that vasculogenesis has a significant contribution to vessel
formation in tumours. EPCs, and other BMDCs such as tumour associated macrophages
(TAMs), mesenchymal progenitor cells (MPC), monocytes, are thought to participate in tu‐
mour vascularization in varying degrees, and are common components of the tumour stro‐
ma [91-95]. These cells can actively be recruited to the site of neovascularization [96], and
reside there to promote angiogenesis or differentiate into vascular EC themselves. This proc‐
ess is further propagated by chronic inflammation of the tumour microenvironment[97].
Furthermore, tissue resident stem cells may contribute to angiogenesis as was shown to be
the case in renal cancinoma’s[98].
Adding to the mechanism of vasculogenesis and the role of stem cells, is an active role for
tumour cells themselves. A heterogeneous malignant tumour is often characterized by sub‐
populations of cancer stem cells (CSCs) that have great self-renewal and differentiation ca‐
pacity, similar to normal stem cells[99, 100]. These CMCs have the ability to acquire an
endothelial progenitor phenotype, and function as vascular ECs, which benefits tumour vas‐
cularization and proliferation[101, 102]. This practise is generally dependent on conditions
such as hypoxia, where tumour cells find themselves in acute need of supply and transdif‐
ferentiate in vascular progenitors[103-105]. Vascular mimicry is a remarkable demonstration
of this CSC-trait. Tumour cells in this process align into channel-like structures, gain EC
gene expression, acquire and EC phenotype, and roughly function as blood vessel (fig. 3B).
Suggested mechanisms by which tumour cells can differentiate into vascular progenitor in‐
clude signalling through VEGF and IKKβ [102, 106].
3.3. Dysregulation of transcriptional angiogenic pathways
3.3.1. Ets transcription factors
Many Ets transcription factors have a suggested or confirmed role in tumour angiogenesis
and progression. Probably the most obvious Ets members to be involved in tumorigenesis
are Fli1 and ERG, which have been acknowledged for their role in embryonic angiogenesis
and vasculogenesis in a previous section of this chapter, but also ETS1/2 and several mem‐
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bers of the ternary complex factor (TCF) subfamily. These transcription factors have been
shown to be overexpressed in tumour cells of divergent cancer types, and to facilitate tu‐
mour progression, vascularization and invasion by regulation of growth factor responsive‐
ness and MMP expression [107-112] (fig. 3C).
With the recently discovery of tumour associated vascular ECs, however, it is imminent that
key players of cell fate determination contribute to tumour induced neo-vascularization. The
master regulator of endothelial and haematopoietic cell specification, Etv2, is only transient‐
ly expressed during embryonic development, as further angiogenesis generally occurs
through proliferation of pre-existing vasculature. As Etv2 activity is absolutely critical for
the specification of ECs, it is conceivable that transdifferentiation of tumour cells and specifi‐
cation and/or mobilization of bone marrow derived progenitors, requires Etv2 activity in tu‐
mour angiogenesis[91] (fig. 3c).
Although little is known about the actual expression levels of Etv2 in tumour cells or their
microenvironment, several direct target genes or other downstream Etv2 targets are upregu‐
lated in tumour tissue. The Ang-2/Tie-2 system, for example, is often strongly activated in
endothelial cells of tumour associated remodelling vessels, leading to increased angiogene‐
sis and proliferation[93, 113-115]. MMPs are known to facilitate a broad range of vascular
events by ECM remodelling and paving the tumour stroma to promote angiogenesis, and
MMP overexpression is instrumental to progression of distinct cancer types[116, 117]. Etv2
can also directly activate the MMP-1 promoter, and MMP-1 is often overexpressed in cancer
as are many others[118-121].
Other Etv2 targets, many of which carry the FOX:ETS motif in their promoter, are ubiqui‐
tously dysregulated during tumour angiogenesis[122-126]. It is not clear whether this is
Etv2-dependent, but it has been shown that Etv2 activity can induce ectopic expression of
these genes in embryonic development, and it is conceivable that Etv2 function is recapitu‐
lated and exploited in tumour vasculogenesis and angiogenesis. This could explain the
transdifferentiation capacity of tumour cells that contribute to the vascular progenitor popu‐
lation, and the recruitment of BMDCs as Etv2 activity specifies EC and haematopoietic line‐
ages from stem cells in the mesoderm. In addition, putative Etv2 targets during tumour
angiogenesis have extensive crosstalk with growth factor signalling, which further endorses
the suggested role and significance of Etv2 in this process[127].
3.3.2. Forkhead transcription factors
The presence and role  of  FoxC2 in  tumour angiogenesis  has  been fairly  well  character‐
ized over the past few years, and it has been shown that the expression of FoxC2 in tu‐
mour endothelium coincides with neovascularization. This further supports the notion of
Etv2  recurrence  during  tumour  vascularization  because  of  the  synergistic  function  be‐
tween these transcription factors  in  regulating endothelial  genes expression through the
FOX:ETS motif.
FoxC2 overexpression is associated with aggressive human cancers, and has been shown to
be overexpressed in mammary breast cancer cells in vitro where it directly promotes a meta‐
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stasis phenotype[128]. More recently, FoxC2 was detected in the tumour ECs of human and
mouse melanomas, and it therefore hypothesized that FoxC2 directly contributes to tumour
angiogenesis[129]. In a B16 melanoma mouse model, the high expression level of FoxC2 in
tumour cells and endothelium correlates with the induced expression of a set of angiogenic
factors, such as Notch ligand Dll4, MMP-2, Pdgfβ and VEGF. Deleting one copy of FoxC2
causes reduction of their expression levels, and these FoxC2 heterozygous mutants also dis‐
play reduced angiogenesis and correspondingly perturbed tumour growth with signs of tu‐
mour necrosis [129]. This is in line with the roles of the suggested targets of FoxC2 in
tumour neovascularization[127, 130], and the pro-migratory and angiogenic phenotype of
FoxC2 overexpressing ECs[129, 131] (fig 3c).
Tumour-induced endothelial to mesenchymal transition can promote FoxC2 expression,
which feeds back into further mesenchymal differentiation[128, 132]. This can for a part ex‐
plain the pro-tumorigenic character of FoxC2, as it increases the ability of tumour ECs to mi‐
grate and proliferate, and prevents entry of tumour ECs into a quiescent state. Interestingly,
FoxC2 heterozygous mutant mice indeed show a reduced amount of tumour-associated fi‐
broblasts, corroborating this hypothesis[129]. FoxC2 may further contribute to tumour an‐
giogenesis by recruiting mesenchymal stem cells[133], or endothelial progenitor cells [134],
although this has yet to be determined.
Interestingly, FoxC1 is also upregulated in some tumour but its role in in tumour angiogene‐
sis is unclear, as deletion of one copy of FoxC 1in mice does not seem to affect melanoma
tumour growth or angiogenesis[129]. Also, neither FoxC1 nor FoxC2 explicitly affect tumour
lymphangiogenesis as lymphatic marker Lyve-1 and Prox1 expression levels are independ‐
ent of FoxC1/2 activity in melanoma tumours[129].
FoxO  transcription  factors  operate,  in  contrast  to  FoxC1,  as  tumour  suppres‐
sors[135-137].  Their function in mediating PI3K-AKT and HIF signalling make them key
regulators of cell  cycle and apoptosis,  and therefore, inactivation of FoxO’s is frequently
observed in cancer[136,  138-141].  Mouse studies have revealed that  FoxOs display func‐
tional  redundancy  in  tumour  suppression  and  vascular  homeostasis,  and  triple  FoxO
knockout (FoxO1,  FoxO3,  FoxO4) mice develop aggressive tumours with a poor surviv‐
al  rate,  and  have  widely  altered  expression  levels  of  EC-survival  and  vascular
genes[137].  FoxO1 is  required for  embryonic  vascular  development,  and its  inactivation
in  cancer  has  repercussions  on  tumour  vascularization,  which  is  confirmed by  vascular
remodelling  defects  in  FoxO1-null  mice  and  their  established  crosstalk  with  VEGF-sig‐
nalling[39].  This  instigates  a  paradox  wherein  tumour  cells  gain  ‘immortality’  through
FoxO  inactivation,  and  simultaneously  seem  to  lose  vessel  functionalization  via  the
same mechanism[39, 141-143].
On  a  particular  note,  FoxO3  depletion  in  tumour  cells  can  attenuate  migration  due  to
reduction  in  MMP  expression,  leading  to  decreased  tumour  size[144].  Henceforth,  the
compound  FoxO  alterations  in  tumours,  and  modifications  to  specific  Fox  members,
must  be further explored to fully appreciate the contexts  dependent roles of  these tran‐
scription factors.
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3.3.3. SoxF transcription factors
SOXF is expressed transiently in the developing endothelium and then again during patho‐
logical conditions, such as wound healing where SOX18 is reexpressed in the capillary endo‐
thelium[145], and in tumorigenesis where SOX18 is reexpressed in the tumour stroma[146],
including the blood and lymphatic vasculature[52, 147]. Recently, SOXF transcription factors
have emerged as novel prognostic markers during gastric cancer progression, as SOX7,
SOX17 and particularly SOX18 are frequently overexpressed in gastric tumour tissue of hu‐
man cancer patients, and survival rates are considerably lower for patients with SOX18 posi‐
tive tumours [146].
The role of Sox18 in tumour angiogenesis has been studied in SOX18-null, and SOXF loss of
function (SOX18 dominant negative mutant-) mice. These studies revealed that melanoma
tumours grow more slowly in absence of SOX18 protein or function in vivo, with a corre‐
sponding reduction in tumour associated microvessel density[52] (fig. 3c). This was further
illustrated in vitro, where ECs and human breast cancer cells with the dominant negative
form of SOX18 proliferate poorly, and tube formation of ECs is impaired, which could be
improved by overexpressing functional SOX18[52].
SOX18 has also been shown to directly facilitate the metastatic spread of tumour cells to the
sentinel lymph node in mice[147]. This is likely to be achieved by promoting neolymphan‐
giogenesis in the tumour microenvironment and thereby paving the way for tumour cell mi‐
gration towards the draining lymph node. During tumour growth, SOX18 has been shown
to be reexpressed in LECs and is suggested to promote lymphatic vascular expansion[147].
Indeed, SOX18 heterozygous mutant mice have reduced lymphatic vessel density, which is
accompanied by a decrease in lymphatic drainage and sentinel lymph node metastasis[147].
Taken together, these observations allocate an important role to SOX18 and possibly other
SOXF transcription factors in regulation tumour vascularization. A recent finding descibes
that SOX18 expression in tumour tissue is regulated on an epigenetic level by multiple states
of promoter-methylation, which underlines the intricacy and divergency of transcriptional
programmes in tumours[148]. With a role for SOXF members in arteriovenous specification,
angiogenesis and lymphangiogenesis, their dysregulation in tumour settings might be a pa‐
rameter influencing the heterogeneity and overabundance of tumour vasculature.
4. Concluding remarks
The blood and lymphatic vascular systems are crucial in higher vertebrates for the transport
of fluids, oxygen, signalling molecules, immune cells, waste material and other components
that maintain homeostasis in the body. These systems develop very early on during embry‐
onic development and are orchestrated by a finely tuned combination of transcriptional reg‐
ulators that can flick cell fate switches.
The transcriptional networks that underlie EC specification are usually transient or at least
very well ordered in the embryo, but this all changes in tumour settings where they are dis‐
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torted and exploited to induce chronic angiogenesis and vasculogenesis. Although most at‐
tention in therapeutic cancer research over the years has gone to growth factor signalling or
other downstream players of proliferation, migration and morphogenesis there seems to be
an emerging paradigm shift in studying both prognostic and therapeutic potential of funda‐
mental transcription factors. The ETS, Forkhead, and SOXF transcription factors discussed
in this overview are in many ways associated with tumour proliferation and vascularization.
Studies in developmental biology have laid the groundwork for further study of transcrip‐
tion factors dysregulation in tumours. Remarkably, there is a high level over crosstalk with
traditional VEGF signalling either through increased VEGF bio-availability, transduction, or
responsiveness within these transcriptional networks.
In the years to come, these transcription factors will expectantly further develop as prognos‐
tic tools for tumorigenesis and possibly arise as molecular targets for treatment of malignant
tumours. At the very least, studying these fundamental regulators in cancer will add to our
understanding of tumour origins and the tools they utilize to achieve proliferation, angio‐
genesis, and malignancy.
Author details
Jeroen Overman and Mathias François
*Address all correspondence to: m.francois@imb.uq.edu.au
Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia
References
[1] Choi, K., et al., A common precursor for hematopoietic and endothelial cells. Development,
1998. 125(4): p. 725-732.
[2] Huber, T.L., et al., Haemangioblast commitment is initiated in the primitive streak of the
mouse embryo. Nature, 2004. 432(7017): p. 625-30.
[3] Vogeli, K.M., et al., A common progenitor for haematopoietic and endothelial lineages in the
zebrafish gastrula. Nature, 2006. 443(7109): p. 337-9.
[4] Shin, M., H. Nagai, and G. Sheng, Notch mediates Wnt and BMP signals in the early sep‐
aration of smooth muscle progenitors and blood/endothelial common progenitors. Develop‐
ment, 2009. 136(4): p. 595-603.
[5] Lancrin, C., et al., The haemangioblast generates haematopoietic cells through a haemogenic
endothelium stage. Nature, 2009. 457(7231): p. 892-5.
[6] Vodyanik, M.A., et al., A mesoderm-derived precursor for mesenchymal stem and endothe‐
lial cells. Cell Stem Cell, 2010. 7(6): p. 718-29.
Research Directions in Tumor Angiogenesis18
[7] Friedl, P. and S. Alexander, Cancer invasion and the microenvironment: plasticity and
reciprocity. Cell, 2011. 147(5): p. 992-1009.
[8] Kirschmann, D.A., et al., Molecular pathways: vasculogenic mimicry in tumor cells: diag‐
nostic and therapeutic implications. Clin Cancer Res, 2012. 18(10): p. 2726-32.
[9] Oliver, G. and R.S. Srinivasan, Endothelial cell plasticity: how to become and remain a
lymphatic endothelial cell. Development, 2010. 137(3): p. 363-72.
[10] Sabin, F.R., Preliminary note on the differentiation of angioblasts and the method by which
they produce blood-vessels, blood-plasma and red blood-cells as seen in the living chick. 1917.
J Hematother Stem Cell Res, 2002. 11(1): p. 5-7.
[11] Ferkowicz, M.J. and M.C. Yoder, Blood island formation: longstanding observations and
modern interpretations. Exp Hematol, 2005. 33(9): p. 1041-7.
[12] Haar, J.L. and G.A. Ackerman, A phase and electron microscopic study of vasculogenesis
and erythropoiesis in the yolk sac of the mouse. Anat Rec, 1971. 170(2): p. 199-223.
[13] Xu, K. and O. Cleaver, Tubulogenesis during blood vessel formation. Semin Cell Dev Biol,
2011. 22(9): p. 993-1004.
[14] Zovein, A.C., et al., Beta1 integrin establishes endothelial cell polarity and arteriolar lumen
formation via a Par3-dependent mechanism. Dev Cell, 2010. 18(1): p. 39-51.
[15] Strilic, B., et al., The molecular basis of vascular lumen formation in the developing mouse
aorta. Dev Cell, 2009. 17(4): p. 505-15.
[16] Xu, K., et al., Blood vessel tubulogenesis requires Rasip1 regulation of GTPase signaling.
Dev Cell, 2011. 20(4): p. 526-39.
[17] Kamei, M., et al., Endothelial tubes assemble from intracellular vacuoles in vivo. Nature,
2006. 442(7101): p. 453-6.
[18] Blum, Y., et al., Complex cell rearrangements during intersegmental vessel sprouting and
vessel fusion in the zebrafish embryo. Dev Biol, 2008. 316(2): p. 312-22.
[19] Wang, Y., et al., Moesin1 and Ve-cadherin are required in endothelial cells during in vivo
tubulogenesis. Development, 2010. 137(18): p. 3119-28.
[20] Davis, G.E. and C.W. Camarillo, An alpha 2 beta 1 integrin-dependent pinocytic mecha‐
nism involving intracellular vacuole formation and coalescence regulates capillary lumen and
tube formation in three-dimensional collagen matrix. Exp Cell Res, 1996. 224(1): p. 39-51.
[21] Jakobsson, L., et al., Endothelial cells dynamically compete for the tip cell position during
angiogenic sprouting. Nat Cell Biol, 2010. 12(10): p. 943-53.
[22] Wei, G.H., et al., Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo.
EMBO J, 2010. 29(13): p. 2147-60.
[23] Pham, V.N., et al., Combinatorial function of ETS transcription factors in the developing
vasculature. Dev Biol, 2007. 303(2): p. 772-83.
Transcriptional Modulation of Tumour Induced Angiogenesis
http://dx.doi.org/10.5772/54055
19
[24] De Val, S., et al., Combinatorial regulation of endothelial gene expression by ets and forkhead
transcription factors. Cell, 2008. 135(6): p. 1053-64.
[25] Pimanda, J.E., et al., Gata2, Fli1, and Scl form a recursively wired gene-regulatory circuit
during early hematopoietic development. Proc Natl Acad Sci U S A, 2007. 104(45): p.
17692-7.
[26] Charlot, C., et al., A review of post-translational modifications and subcellular localization
of Ets transcription factors: possible connection with cancer and involvement in the hypoxic
response. Methods Mol Biol, 2010. 647: p. 3-30.
[27] Ferdous, A., et al., Nkx2-5 transactivates the Ets-related protein 71 gene and specifies an
endothelial/endocardial fate in the developing embryo. Proc Natl Acad Sci U S A, 2009.
106(3): p. 814-9.
[28] Kataoka, H., et al., Etv2/ER71 induces vascular mesoderm from Flk1+PDGFRalpha+ primi‐
tive mesoderm. Blood, 2011. 118(26): p. 6975-86.
[29] Hart, A., et al., Fli-1 is required for murine vascular and megakaryocytic development and is
hemizygously deleted in patients with thrombocytopenia. Immunity, 2000. 13(2): p. 167-77.
[30] Hollenhorst, P.C., et al., Genome-wide analyses reveal properties of redundant and specific
promoter occupancy within the ETS gene family. Genes Dev, 2007. 21(15): p. 1882-94.
[31] Birdsey, G.M., et al., Transcription factor Erg regulates angiogenesis and endothelial apop‐
tosis through VE-cadherin. Blood, 2008. 111(7): p. 3498-506.
[32] Birdsey, G.M., et al., The transcription factor Erg regulates expression of histone deacetylase
6 and multiple pathways involved in endothelial cell migration and angiogenesis. Blood,
2012. 119(3): p. 894-903.
[33] Lee, D., et al., ER71 acts downstream of BMP, Notch, and Wnt signaling in blood and vessel
progenitor specification. Cell Stem Cell, 2008. 2(5): p. 497-507.
[34] Kappel, A., et al., Identification of vascular endothelial growth factor (VEGF) receptor-2
(Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific
transcription in transgenic mice. Blood, 1999. 93(12): p. 4284-92.
[35] Mammoto, A., et al., A mechanosensitive transcriptional mechanism that controls angio‐
genesis. Nature, 2009. 457(7233): p. 1103-8.
[36] Simon, M.P., R. Tournaire, and J. Pouyssegur, The angiopoietin-2 gene of endothelial cells
is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central
factors GATA-2 and Ets-1. J Cell Physiol, 2008. 217(3): p. 809-18.
[37] Linnemann, A.K., et al., Genetic framework for GATA factor function in vascular biology.
Proc Natl Acad Sci U S A, 2011. 108(33): p. 13641-6.
[38] Veldman, M.B. and S. Lin, Etsrp/Etv2 is directly regulated by Foxc1a/b in the zebrafish an‐
gioblast. Circ Res, 2012. 110(2): p. 220-9.
Research Directions in Tumor Angiogenesis20
[39] Furuyama, T., et al., Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice. J Biol Chem,
2004. 279(33): p. 34741-9.
[40] Wang, Y., et al., Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis.
Nature, 2010. 465(7297): p. 483-6.
[41] Matsukawa, M., et al., Different roles of Foxo1 and Foxo3 in the control of endothelial cell
morphology. Genes Cells, 2009. 14(10): p. 1167-81.
[42] Calnan, D.R. and A. Brunet, The FoxO code. Oncogene, 2008. 27(16): p. 2276-88.
[43] Seo, S., et al., The forkhead transcription factors, Foxc1 and Foxc2, are required for arterial
specification and lymphatic sprouting during vascular development. Dev Biol, 2006. 294(2):
p. 458-70.
[44] Fischer, A., et al., The Notch target genes Hey1 and Hey2 are required for embryonic vascu‐
lar development. Genes Dev, 2004. 18(8): p. 901-11.
[45] Seo, S., et al., Forkhead box transcription factor FoxC1 preserves corneal transparency by
regulating vascular growth. Proc Natl Acad Sci U S A, 2012. 109(6): p. 2015-20.
[46] Skarie, J.M. and B.A. Link, FoxC1 is essential for vascular basement membrane integrity
and hyaloid vessel morphogenesis. Invest Ophthalmol Vis Sci, 2009. 50(11): p. 5026-34.
[47] Fang, J., et al., Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are
responsible for the hereditary lymphedema-distichiasis syndrome. Am J Hum Genet, 2000.
67(6): p. 1382-8.
[48] Mellor, R.H., et al., Mutations in FOXC2 are strongly associated with primary valve failure
in veins of the lower limb. Circulation, 2007. 115(14): p. 1912-20.
[49] Petrova, T.V., et al., Defective valves and abnormal mural cell recruitment underlie lym‐
phatic vascular failure in lymphedema distichiasis. Nat Med, 2004. 10(9): p. 974-81.
[50] Sabine, A., et al., Mechanotransduction, PROX1, and FOXC2 cooperate to control connex‐
in37 and calcineurin during lymphatic-valve formation. Dev Cell, 2012. 22(2): p. 430-45.
[51] Norrmen, C., et al., FOXC2 controls formation and maturation of lymphatic collecting ves‐
sels through cooperation with NFATc1. J Cell Biol, 2009. 185(3): p. 439-57.
[52] Young, N., et al., Effect of disrupted SOX18 transcription factor function on tumor growth,
vascularization, and endothelial development. J Natl Cancer Inst, 2006. 98(15): p. 1060-7.
[53] Bowles, J., G. Schepers, and P. Koopman, Phylogeny of the SOX family of developmental
transcription factors based on sequence and structural indicators. Dev Biol, 2000. 227(2): p.
239-55.
[54] Hosking, B.M., et al., Trans-activation and DNA-binding properties of the transcription
factor, Sox-18. Nucleic Acids Res, 1995. 23(14): p. 2626-8.
[55] Wegner, M., From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res,
1999. 27(6): p. 1409-20.
Transcriptional Modulation of Tumour Induced Angiogenesis
http://dx.doi.org/10.5772/54055
21
[56] Hosking, B.M., et al., SOX18 directly interacts with MEF2C in endothelial cells. Biochem
Biophys Res Commun, 2001. 287(2): p. 493-500.
[57] Wilson, M. and P. Koopman, Matching SOX: partner proteins and co-factors of the SOX
family of transcriptional regulators. Curr Opin Genet Dev, 2002. 12(4): p. 441-6.
[58] Hosking, B., et al., Sox7 and Sox17 are strain-specific modifiers of the lymphangiogenic de‐
fects caused by Sox18 dysfunction in mice. Development, 2009. 136(14): p. 2385-91.
[59] Pennisi, D., et al., Mutations in Sox18 underlie cardiovascular and hair follicle defects in
ragged mice. Nat Genet, 2000. 24(4): p. 434-7.
[60] Cermenati, S., et al., Sox18 and Sox7 play redundant roles in vascular development. Blood,
2008. 111(5): p. 2657-66.
[61] Herpers, R., et al., Redundant roles for sox7 and sox18 in arteriovenous specification in ze‐
brafish. Circ Res, 2008. 102(1): p. 12-5.
[62] Fontijn, R.D., et al., SOX-18 controls endothelial-specific claudin-5 gene expression and bar‐
rier function. Am J Physiol Heart Circ Physiol, 2008. 294(2): p. H891-900.
[63] Hosking, B.M., et al., The VCAM-1 gene that encodes the vascular cell adhesion molecule is
a target of the Sry-related high mobility group box gene, Sox18. J Biol Chem, 2004. 279(7):
p. 5314-22.
[64] Hoeth, M., et al., The transcription factor SOX18 regulates the expression of matrix metal‐
loproteinase 7 and guidance molecules in human endothelial cells. PLoS One, 2012. 7(1): p.
e30982.
[65] Samant, G.V., et al., Sox factors transcriptionally regulate ROBO4 gene expression in de‐
veloping vasculature in zebrafish. J Biol Chem, 2011. 286(35): p. 30740-7.
[66] Bedell, V.M., et al., roundabout4 is essential for angiogenesis in vivo. Proc Natl Acad Sci
U S A, 2005. 102(18): p. 6373-8.
[67] Matsui, T., et al., Redundant roles of Sox17 and Sox18 in postnatal angiogenesis in mice. J
Cell Sci, 2006. 119(Pt 17): p. 3513-26.
[68] Francois, M., et al., Sox18 induces development of the lymphatic vasculature in mice. Na‐
ture, 2008. 456(7222): p. 643-7.
[69] Srinivasan, R.S., et al., The nuclear hormone receptor Coup-TFII is required for the initia‐
tion and early maintenance of Prox1 expression in lymphatic endothelial cells. Genes Dev,
2010. 24(7): p. 696-707.
[70] Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. Cell, 2011.
144(5): p. 646-74.
[71] Schreiber, R.D., L.J. Old, and M.J. Smyth, Cancer immunoediting: integrating immunity's
roles in cancer suppression and promotion. Science, 2011. 331(6024): p. 1565-70.
Research Directions in Tumor Angiogenesis22
[72] Pries, A.R., et al., The shunt problem: control of functional shunting in normal and tumour
vasculature. Nat Rev Cancer, 2010. 10(8): p. 587-93.
[73] Kamoun, W.S., et al., Simultaneous measurement of RBC velocity, flux, hematocrit and
shear rate in vascular networks. Nat Methods, 2010. 7(8): p. 655-60.
[74] Padera, T.P., et al., Pathology: cancer cells compress intratumour vessels. Nature, 2004.
427(6976): p. 695.
[75] Heldin, C.H., et al., High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev
Cancer, 2004. 4(10): p. 806-13.
[76] Eberhard, A., et al., Heterogeneity of angiogenesis and blood vessel maturation in human
tumors: implications for antiangiogenic tumor therapies. Cancer Res, 2000. 60(5): p.
1388-93.
[77] Yu, J.L., et al., Heterogeneous vascular dependence of tumor cell populations. Am J Pathol,
2001. 158(4): p. 1325-34.
[78] Morikawa, S., et al., Abnormalities in pericytes on blood vessels and endothelial sprouts in
tumors. Am J Pathol, 2002. 160(3): p. 985-1000.
[79] Gerhardt, H. and H. Semb, Pericytes: gatekeepers in tumour cell metastasis? J Mol Med
(Berl), 2008. 86(2): p. 135-44.
[80] Alitalo, K., T. Tammela, and T.V. Petrova, Lymphangiogenesis in development and hu‐
man disease. Nature, 2005. 438(7070): p. 946-53.
[81] Achen, M.G., B.K. McColl, and S.A. Stacker, Focus on lymphangiogenesis in tumor meta‐
stasis. Cancer Cell, 2005. 7(2): p. 121-7.
[82] Soda, Y., et al., Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc
Natl Acad Sci U S A, 2011. 108(11): p. 4274-80.
[83] Adams, R.H. and K. Alitalo, Molecular regulation of angiogenesis and lymphangiogenesis.
Nat Rev Mol Cell Biol, 2007. 8(6): p. 464-78.
[84] Lohela, M., et al., VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.
Curr Opin Cell Biol, 2009. 21(2): p. 154-65.
[85] Skog, J., et al., Glioblastoma microvesicles transport RNA and proteins that promote tumour
growth and provide diagnostic biomarkers. Nat Cell Biol, 2008. 10(12): p. 1470-6.
[86] Valadi, H., et al., Exosome-mediated transfer of mRNAs and microRNAs is a novel mecha‐
nism of genetic exchange between cells. Nat Cell Biol, 2007. 9(6): p. 654-9.
[87] Balaj, L., et al., Tumour microvesicles contain retrotransposon elements and amplified onco‐
gene sequences. Nat Commun, 2011. 2: p. 180.
[88] Millimaggi, D., et al., Tumor vesicle-associated CD147 modulates the angiogenic capability
of endothelial cells. Neoplasia, 2007. 9(4): p. 349-57.
Transcriptional Modulation of Tumour Induced Angiogenesis
http://dx.doi.org/10.5772/54055
23
[89] Deregibus, M.C., et al., Endothelial progenitor cell derived microvesicles activate an angio‐
genic program in endothelial cells by a horizontal transfer of mRNA. Blood, 2007. 110(7): p.
2440-8.
[90] Collino, F., et al., Microvesicles derived from adult human bone marrow and tissue specific
mesenchymal stem cells shuttle selected pattern of miRNAs. PLoS One, 2010. 5(7): p.
e11803.
[91] Li Calzi, S., et al., EPCs and pathological angiogenesis: when good cells go bad. Microvasc
Res, 2010. 79(3): p. 207-16.
[92] Joyce, J.A. and J.W. Pollard, Microenvironmental regulation of metastasis. Nat Rev Can‐
cer, 2009. 9(4): p. 239-52.
[93] De Palma, M., et al., Tie2 identifies a hematopoietic lineage of proangiogenic monocytes re‐
quired for tumor vessel formation and a mesenchymal population of pericyte progenitors.
Cancer Cell, 2005. 8(3): p. 211-26.
[94] Gao, D., et al., Endothelial progenitor cells control the angiogenic switch in mouse lung
metastasis. Science, 2008. 319(5860): p. 195-8.
[95] Karnoub, A.E., et al., Mesenchymal stem cells within tumour stroma promote breast cancer
metastasis. Nature, 2007. 449(7162): p. 557-63.
[96] Grunewald, M., et al., VEGF-induced adult neovascularization: recruitment, retention, and
role of accessory cells. Cell, 2006. 124(1): p. 175-89.
[97] Mantovani, A., et al., Cancer-related inflammation. Nature, 2008. 454(7203): p. 436-44.
[98] Bruno, S., et al., CD133+ renal progenitor cells contribute to tumor angiogenesis. Am J
Pathol, 2006. 169(6): p. 2223-35.
[99] Fang, D., et al., A tumorigenic subpopulation with stem cell properties in melanomas. Can‐
cer Res, 2005. 65(20): p. 9328-37.
[100] Pezzolo, A., et al., Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-
derived endothelial cells. Cell Res, 2011. 21(10): p. 1470-86.
[101] Gao, J.X., Cancer stem cells: the lessons from pre-cancerous stem cells. J Cell Mol Med,
2008. 12(1): p. 67-96.
[102] Alvero, A.B., et al., Stem-like ovarian cancer cells can serve as tumor vascular progenitors.
Stem Cells, 2009. 27(10): p. 2405-13.
[103] Yao, X.H., Y.F. Ping, and X.W. Bian, Contribution of cancer stem cells to tumor vasculo‐
genic mimicry. Protein Cell, 2011. 2(4): p. 266-72.
[104] El Hallani, S., et al., A new alternative mechanism in glioblastoma vascularization: tubular
vasculogenic mimicry. Brain, 2010. 133(Pt 4): p. 973-82.
[105] Shen, R., et al., Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS
One, 2008. 3(2): p. e1652.
Research Directions in Tumor Angiogenesis24
[106] Kusumbe, A.P., A.M. Mali, and S.A. Bapat, CD133-expressing stem cells associated with
ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature.
Stem Cells, 2009. 27(3): p. 498-508.
[107] Nakayama, T., et al., Expression of the Ets-1 proto-oncogene in human gastric carcinoma:
correlation with tumor invasion. Am J Pathol, 1996. 149(6): p. 1931-9.
[108] Alipov, G., et al., Overexpression of Ets-1 proto-oncogene in latent and clinical prostatic
carcinomas. Histopathology, 2005. 46(2): p. 202-8.
[109] Saeki, H., et al., Concurrent overexpression of Ets-1 and c-Met correlates with a phenotype
of high cellular motility in human esophageal cancer. Int J Cancer, 2002. 98(1): p. 8-13.
[110] Pourtier-Manzanedo, A., et al., Expression of an Ets-1 dominant-negative mutant perturbs
normal and tumor angiogenesis in a mouse ear model. Oncogene, 2003. 22(12): p.
1795-806.
[111] Potikyan, G., et al., EWS/FLI1 regulates tumor angiogenesis in Ewing's sarcoma via sup‐
pression of thrombospondins. Cancer Res, 2007. 67(14): p. 6675-84.
[112] Carver, B.S., et al., Aberrant ERG expression cooperates with loss of PTEN to promote can‐
cer progression in the prostate. Nat Genet, 2009. 41(5): p. 619-24.
[113] Mitsuhashi, N., et al., Angiopoietins and Tie-2 expression in angiogenesis and proliferation
of human hepatocellular carcinoma. Hepatology, 2003. 37(5): p. 1105-13.
[114] Peters, K.G., et al., Expression of Tie2/Tek in breast tumour vasculature provides a new
marker for evaluation of tumour angiogenesis. Br J Cancer, 1998. 77(1): p. 51-6.
[115] Staton, C.A., et al., Angiopoietins 1 and 2 and Tie-2 receptor expression in human ductal
breast disease. Histopathology, 2011. 59(2): p. 256-63.
[116] Littlepage, L.E., et al., Matrix metalloproteinases contribute distinct roles in neuroendo‐
crine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res, 2010.
70(6): p. 2224-34.
[117] Egeblad, M. and Z. Werb, New functions for the matrix metalloproteinases in cancer pro‐
gression. Nat Rev Cancer, 2002. 2(3): p. 161-74.
[118] Murray, G.I., et al., Matrix metalloproteinase-1 is associated with poor prognosis in colorec‐
tal cancer. Nat Med, 1996. 2(4): p. 461-2.
[119] Sauter, W., et al., Matrix metalloproteinase 1 (MMP1) is associated with early-onset lung
cancer. Cancer Epidemiol Biomarkers Prev, 2008. 17(5): p. 1127-35.
[120] Pallavi, S.K., et al., Notch and Mef2 synergize to promote proliferation and metastasis
through JNK signal activation in Drosophila. EMBO J, 2012. 31(13): p. 2895-907.
[121] De Haro, L. and R. Janknecht, Functional analysis of the transcription factor ER71 and its
activation of the matrix metalloproteinase-1 promoter. Nucleic Acids Res, 2002. 30(13): p.
2972-9.
Transcriptional Modulation of Tumour Induced Angiogenesis
http://dx.doi.org/10.5772/54055
25
[122] Hendrix, M.J., et al., Expression and functional significance of VE-cadherin in aggressive
human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci U S A, 2001.
98(14): p. 8018-23.
[123] Wallez, Y., I. Vilgrain, and P. Huber, Angiogenesis: the VE-cadherin switch. Trends Car‐
diovasc Med, 2006. 16(2): p. 55-9.
[124] Ostrander, J.H., et al., Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-
induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Res, 2007.
67(9): p. 4199-209.
[125] Hu, W., et al., Biological roles of the Delta family Notch ligand Dll4 in tumor and endothe‐
lial cells in ovarian cancer. Cancer Res, 2011. 71(18): p. 6030-9.
[126] Hovinga, K.E., et al., Inhibition of notch signaling in glioblastoma targets cancer stem cells
via an endothelial cell intermediate. Stem Cells, 2010. 28(6): p. 1019-29.
[127] Rapisarda, A. and G. Melillo, Role of the VEGF/VEGFR axis in cancer biology and thera‐
py. Adv Cancer Res, 2012. 114: p. 237-67.
[128] Mani, S.A., et al., Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is
associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A, 2007.
104(24): p. 10069-74.
[129] Sano, H., et al., The Foxc2 transcription factor regulates tumor angiogenesis. Biochem Bio‐
phys Res Commun, 2010. 392(2): p. 201-6.
[130] Taniwaki, K., et al., Stroma-derived matrix metalloproteinase (MMP)-2 promotes mem‐
brane type 1-MMP-dependent tumor growth in mice. Cancer Res, 2007. 67(9): p. 4311-9.
[131] Hayashi, H., et al., The Foxc2 transcription factor regulates angiogenesis via induction of
integrin beta3 expression. J Biol Chem, 2008. 283(35): p. 23791-800.
[132] Zeisberg, E.M., et al., Discovery of endothelial to mesenchymal transition as a source for
carcinoma-associated fibroblasts. Cancer Res, 2007. 67(21): p. 10123-8.
[133] Crisan, M., et al., A perivascular origin for mesenchymal stem cells in multiple human or‐
gans. Cell Stem Cell, 2008. 3(3): p. 301-13.
[134] Li, D., et al., Foxc2 overexpression enhances benefit of endothelial progenitor cells for inhibit‐
ing neointimal formation by promoting CXCR4-dependent homing. J Vasc Surg, 2011.
53(6): p. 1668-78.
[135] Dansen, T.B. and B.M. Burgering, Unravelling the tumor-suppressive functions of FOXO
proteins. Trends Cell Biol, 2008. 18(9): p. 421-9.
[136] Modur, V., et al., FOXO proteins regulate tumor necrosis factor-related apoptosis inducing
ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem, 2002.
277(49): p. 47928-37.
[137] Paik, J.H., et al., FoxOs are lineage-restricted redundant tumor suppressors and regulate en‐
dothelial cell homeostasis. Cell, 2007. 128(2): p. 309-23.
Research Directions in Tumor Angiogenesis26
[138] Roy, S.K., R.K. Srivastava, and S. Shankar, Inhibition of PI3K/AKT and MAPK/ERK
pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and
apoptosis in pancreatic cancer. J Mol Signal, 2010. 5: p. 10.
[139] Ciechomska, I., et al., Inhibition of Akt kinase signalling and activation of Forkhead are in‐
dispensable for upregulation of FasL expression in apoptosis of glioma cells. Oncogene, 2003.
22(48): p. 7617-27.
[140] Hu, M.C., et al., IkappaB kinase promotes tumorigenesis through inhibition of forkhead
FOXO3a. Cell, 2004. 117(2): p. 225-37.
[141] Aoki, M., H. Jiang, and P.K. Vogt, Proteasomal degradation of the FoxO1 transcriptional
regulator in cells transformed by the P3k and Akt oncoproteins. Proc Natl Acad Sci U S A,
2004. 101(37): p. 13613-7.
[142] Kim, S.Y., et al., Constitutive phosphorylation of the FOXO1 transcription factor in gastric
cancer cells correlates with microvessel area and the expressions of angiogenesis-related mole‐
cules. BMC Cancer, 2011. 11: p. 264.
[143] Lee, B.L., et al., A hypoxia-independent up-regulation of hypoxia-inducible factor-1 by AKT
contributes to angiogenesis in human gastric cancer. Carcinogenesis, 2008. 29(1): p. 44-51.
[144] Storz, P., et al., FOXO3a promotes tumor cell invasion through the induction of matrix met‐
alloproteinases. Mol Cell Biol, 2009. 29(18): p. 4906-17.
[145] Darby, I.A., et al., Sox18 is transiently expressed during angiogenesis in granulation tissue
of skin wounds with an identical expression pattern to Flk-1 mRNA. Lab Invest, 2001.
81(7): p. 937-43.
[146] Eom, B.W., et al., The lymphangiogenic factor SOX 18: a key indicator to stage gastric tu‐
mor progression. Int J Cancer, 2012. 131(1): p. 41-8.
[147] Duong, T., et al., Genetic ablation of SOX18 function suppresses tumor lymphangiogenesis
and metastasis of melanoma in mice. Cancer Res, 2012. 72(12): p. 3105-14.
[148] Azhikina, T., et al., Heterogeneity and degree of TIMP4, GATA4, SOX18, and EGFL7 gene
promoter methylation in non-small cell lung cancer and surrounding tissues. Cancer Genet,
2011. 204(9): p. 492-500.
Transcriptional Modulation of Tumour Induced Angiogenesis
http://dx.doi.org/10.5772/54055
27

